Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21532545 | 0.95 | AKT1 (0.36) | SMN1; SMN2HIF1AAKT1 | |
| SCHEMBL21532714 | 0.91 | OPRD1 (0.33) | SMN1; SMN2HIF1AAKT1ALDH1A1KDM4E | |
| SCHEMBL21532276 | 0.89 | SMN1; SMN2 (0.34) | SMN1; SMN2HIF1AAKT1ALDH1A1 | |
| SCHEMBL21532253 | 0.89 | AKT1 (0.32) | AKT1 | |
| SCHEMBL21532424 | 0.88 | SMN1; SMN2 (0.34) | SMN1; SMN2HIF1AAKT1ALDH1A1KDM4E | |
| SCHEMBL21532621 | 0.88 | KDM4E (0.34) | SMN1; SMN2AKT1ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL21532780 | 0.87 | AKT1 (0.38) | SMN1; SMN2HIF1AAKT1ALDH1A1KDM4E | |
| SCHEMBL21532675 | 0.86 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1KDM4ERGS12USP2 | |
| SCHEMBL21532162 | 0.85 | AVPR1A (0.37) | SMN1; SMN2ALDH1A1KDM4EPOLBHSD17B10 | |
| SCHEMBL21532697 | 0.85 | OPRD1 (0.34) | SMN1; SMN2HIF1AAKT1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11145825-B2 | Condensed cyclic compound and organic light-emitting device including i he same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-10-12 | — | — | US | disclosed |
| US-20190334095-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11145825-B2 | Condensed cyclic compound and organic light-emitting device including i he same | CRY1, CCNT1, CCNA1 | SMN1; SMN2 2430/4885HIF1A 657/4885AKT1 2105/4885 |
| US-20190334095-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNT1, ARL1 | SMN1; SMN2 2103/4885HIF1A 1000/4885AKT1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.